RBC Bioscience

RBC Bioscience Capital Intensity

The Capital Intensity Ratio of RBC Bioscience (6848.TWO) as of Nov 6, 2026 is 372.18 %. In the previous year, Capital Intensity Ratio was 437.06 % — a change of -14.84% (lower).

Capital Intensity

372.18 %

YoY

-14.84%

Last updated:

Capital Intensity Ratio of RBC Bioscience is 2024 372.18 % . Capital Intensity Ratio of RBC Bioscience was 2023 437.06 % . It decreases by -14.84% lower compared to the previous year.

The RBC Bioscience Capital Intensity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Intensity
Date
Capital Intensity
Jan 1, 2018
131.92 TWD
Jan 1, 2019
124.29 TWD
Jan 1, 2020
89.13 TWD
Jan 1, 2021
337.45 TWD
Jan 1, 2022
454.62 TWD
Jan 1, 2023
437.06 TWD
Jan 1, 2024
372.18 TWD
The RBC Bioscience Capital Intensity history
YEARCapital IntensityYoY
372.18 %-14.84%
437.06 %-3.86%
454.62 %+34.72%
337.45 %+278.62%
89.13 %-28.29%
124.29 %-5.78%
131.92 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RBC Bioscience Stock analysis

What does RBC Bioscience do? RBC Bioscience Corp manufactures reagents and devices for life science and molecular diagnosis. The company's products include instruments equipped with ultraviolet sterilization systems for nucleic acid purification and disposable reagent strips and tips that work with built-in control programs for different nucleic acid extraction types. The firm developed nucleic acid purification reagents with cellulose-embedded magnetic beads to improve DNA and RNA purity for blood, bacteria, viruses, and forensic examinations. These products are used for future diagnosis, prevention, tracking, and treatment of diseases. The company sells its instruments and reagents to customers in life science and molecular diagnosis sectors. The instruments feature ultraviolet sterilization systems, while the reagents include disposable strips and tips with varying control programs. The reagents with cellulose-embedded magnetic beads are designed for high-purity nucleic acid extraction from diverse samples including blood, bacteria, viruses, and forensic materials. RBC Bioscience Corp's revenue comes from the sale of instruments and reagents. The instruments are sold to laboratories and medical facilities requiring nucleic acid purification systems. The reagents, including the disposable strips and tips, are sold alongside the instruments or separately for ongoing use in molecular diagnosis processes. RBC Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RBC Bioscience stock

Capital Intensity Ratio of RBC Bioscience is 372.18 % in 2024.

Capital Intensity Ratio of RBC Bioscience changed from 437.06 % to 372.18 %, representing a -14.84% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Capital Intensity Ratio RBC Bioscience since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's RBC Bioscience with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — RBC Bioscience

All Key Metrics — RBC Bioscience